Carl E. Wolf

2 papers in the library · publishing 2013-2015

Papers

Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.

Journal of Analytical Toxicology October 1, 2015 Justin L. Poklis, Sara K Dempsey, Kai Liu et al.

Fifteen metabolites of the designer hallucinogen 25I-NBOMe were identified in mouse liver microsomal preparations and in urine from two intoxicated patients. One patient's urine contained the parent drug and all fifteen metabolites; the other contained only three O-desmethyl metabolites. Two major urinary metabolites were synthesized. The authors recommend using β-glucuronidase hydrolysis before screening and using the metabolite M5 as the primary biomarker for detecting 25I-NBOMe use.

DOI: 10.1093/jat/bkv079 Full text

High‐performance liquid chromatography tandem mass spectrometry method for the determination of 2CC‐NBOMe and 25I‐NBOMe in human serum

Biomedical Chromatography December 1, 2013 Justin L. Poklis, Jezelle Charles, Carl E. Wolf et al.

A new high-performance liquid chromatography triple quadrupole mass spectrometry method was developed to detect and quantify two designer drugs, 2CC-NBOMe and 25I-NBOMe, in the serum of intoxicated emergency department patients. The method uses solid-phase extraction and is linear over 30–2000 pg/mL, with a detection limit of 10 pg/mL for both compounds. Applied to two severely intoxicated patients, serum concentrations of 25I-NBOMe were 250 and 2780 pg/mL. The method is suitable for clinical toxicology testing.

DOI: 10.1002/bmc.2999